Dietary Intervention for Prediabetes
Trial Summary
What is the purpose of this trial?
1 in 3 adults have prediabetes in the United States, and many of them will eventually develop diabetes, which has significant public health and economic costs. However, type 2 diabetes (T2D) and prediabetes are heterogeneous groups with different pathological mechanisms, dysfunctions in different processes, and varied disease trajectories. Patient stratifications into subtypes and personalized nutrition interventions are highly needed but not yet available. Metabolic responses (e.g., glucose excursion) after food intake provide a direct observation of personal metabolic control and its association with T2D. The investigators hope to learn how prediabetes and type 2 diabetes evolve, and specifically what food or exercise can do to mitigate blood sugar response.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are on diabetogenic medications, except for metformin. If you are taking metformin, you can continue using it during the study.
What data supports the effectiveness of the treatment Dietary Intervention for Prediabetes?
Is the dietary intervention for prediabetes safe for humans?
How does the dietary intervention treatment for prediabetes differ from other treatments?
The dietary intervention for prediabetes, focusing on fat-free mass-indexed feeding, is unique because it tailors nutritional intake to an individual's body composition, potentially offering a more personalized approach compared to standard low-calorie or low-glycemic diets. This method emphasizes adjusting dietary habits to improve body composition and metabolic health, which may not be the focus of other nutritional strategies.26101112
Research Team
Yue Wu, PhD
Principal Investigator
Stanford University
Eligibility Criteria
This trial is for generally healthy adults over 18 living near Stanford who have prediabetes or type 2 diabetes managed by diet or metformin. Participants must not be pregnant, have cognitive impairments, malabsorptive disorders, major organ diseases, a history of bariatric surgery, heavy alcohol use, recent significant weight change, or be on certain medications.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Monitoring
Participants use a Continuous Glucose Monitor (CGM) and Fitbit to track blood sugars and activity for 10 days, while following specific dietary and exercise instructions.
Optional Repetition
5 participants may volunteer to repeat the 10-day monitoring cycle three times.
Follow-up
Participants are monitored for changes in metabolic states and glucose levels after the intervention period.
Treatment Details
Interventions
- Dietary intervention
Find a Clinic Near You
Who Is Running the Clinical Trial?
Stanford University
Lead Sponsor